Cite
HARVARD Citation
Weller, M. et al. (n.d.). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet oncology. 18 (10), pp. 1373-1385. [Online].